Artivion Past Earnings Performance

Past criteria checks 0/6

Artivion's earnings have been declining at an average annual rate of -46.5%, while the Medical Equipment industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 5.8% per year.

Key information

-46.5%

Earnings growth rate

-45.2%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth rate5.8%
Return on equity-10.9%
Net Margin-8.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jan 13
Is Artivion (NYSE:AORT) Using Too Much Debt?

Artivion Stock: A First Assessment

Dec 27

Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Nov 23
Investors Still Aren't Entirely Convinced By Artivion, Inc.'s (NYSE:AORT) Revenues Despite 27% Price Jump

Artivion's Ongoing Clinical Studies Could Drive Significant Growth Starting In 2025

Oct 13

Artivion: On-X Sales Double 5-Year Average, Far More Constructive View (Rating Upgrade)

Jul 20

Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

May 10
Artivion's (NYSE:AORT) Returns On Capital Are Heading Higher

Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Mar 09
Artivion (NYSE:AORT) Has A Somewhat Strained Balance Sheet

Artivion Non-GAAP EPS of $0.10 beats by $0.12, revenue of $79.4M misses by $0.77M

Feb 16

Artivion: PROACT Xa Overhang Remains Well In Situ, Reaffirm Hold

Dec 18

Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Sep 29
Artivion (NYSE:AORT) Is Making Moderate Use Of Debt

Artivion: Stopping PROACT Xa Trial Removes Long-Term Growth Driver

Sep 27

Artivion Non-GAAP EPS of -$0.03 misses by $0.06, revenue of $80.34M beats by $3.07M

Aug 04

Is Artivion (NYSE:AORT) Using Too Much Debt?

Jun 27
Is Artivion (NYSE:AORT) Using Too Much Debt?

Is Artivion (NYSE:AORT) Using Too Much Debt?

Mar 25
Is Artivion (NYSE:AORT) Using Too Much Debt?

CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet

Dec 08
CryoLife (NYSE:CRY) Has A Somewhat Strained Balance Sheet

CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 01
CryoLife, Inc. (NYSE:CRY) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

CryoLife (NYSE:CRY) Takes On Some Risk With Its Use Of Debt

Jul 30
CryoLife (NYSE:CRY) Takes On Some Risk With Its Use Of Debt

Revenue & Expenses Breakdown
Beta

How Artivion makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:AORT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23354-3118529
30 Sep 23340-2418029
30 Jun 23329-2817535
31 Mar 23320-2917136
31 Dec 22314-1916639
30 Sep 22314-4117040
30 Jun 22309-1716838
31 Mar 22305-1516338
31 Dec 21299-1516136
30 Sep 21287214533
30 Jun 21280-1214128
31 Mar 21258-1313526
31 Dec 20253-1713724
30 Sep 20255-1414323
30 Jun 20258-1114323
31 Mar 20275-514524
31 Dec 19276214323
30 Sep 19274214824
30 Jun 19271314023
31 Mar 19268114023
31 Dec 18263-314123
30 Sep 18248-512823
30 Jun 18227-512722
31 Mar 18207-211621
31 Dec 17190410119
30 Sep 17182910017
30 Jun 17183119616
31 Mar 17182109415
31 Dec 16180119213
30 Sep 16175107812
30 Jun 1616797611
31 Mar 1615577411
31 Dec 1514647210
30 Sep 1514337410
30 Jun 151443769
31 Mar 151436748
31 Dec 141457749
30 Sep 1414214729
30 Jun 1414115699
31 Mar 1414015689
31 Dec 1314116688
30 Sep 131389688
30 Jun 131357688
31 Mar 131359678

Quality Earnings: AORT is currently unprofitable.

Growing Profit Margin: AORT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: AORT is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Accelerating Growth: Unable to compare AORT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AORT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (8.7%).


Return on Equity

High ROE: AORT has a negative Return on Equity (-10.89%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.